Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups

about

Complex Karyotype in Hematological Diseases: A 6-Year Single Centre Study from Pakistan.

P2860

Q55404461-1323FAF3-EBC0-48B5-A1BF-E29D587AD27B

P2860

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups

Item

http://www.wikidata.org/entity/Q41983363

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Outcomes of 1st Remission Indu ...... ukemia Cytogenetic Risk Groups

@en

type

Item

label

Outcomes of 1st Remission Indu ...... ukemia Cytogenetic Risk Groups

@en

prefLabel

Outcomes of 1st Remission Indu ...... ukemia Cytogenetic Risk Groups

@en

P1476

Outcomes of 1st Remission Indu ...... ukemia Cytogenetic Risk Groups

@en

P2093

Rahela Najam

http://www.w3.org/2001/XMLSchema#string

Samreen Zehra

http://www.w3.org/2001/XMLSchema#string

Tahir Shamsi

http://www.w3.org/2001/XMLSchema#string

Tasneem Farzana

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

Toxicity and response criteria of the Eastern Cooperative Oncology Group

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

Age and acute myeloid leukemia.

Anthracycline dose intensification in acute myeloid leukemia.

Genetic abnormalities and challenges in the treatment of acute myeloid leukemia.

P304

5251-5256

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.22034/APJCP.2016.17.12.5251

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28125870

http://www.w3.org/2001/XMLSchema#string

P932

5454667

http://www.w3.org/2001/XMLSchema#string

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups

about

P2860

P2860

Outcomes of 1st Remission Induction Chemotherapy in Acute Myeloid Leukemia Cytogenetic Risk Groups

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932